Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 10,300 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total value of $10,403.00. Following the completion of the transaction, the insider now directly owns 316,604 shares in the company, valued at $319,770.04. This represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $0.93 on Friday. The stock has a market cap of $171.95 million, a price-to-earnings ratio of -1.11 and a beta of 0.58. The business has a 50 day simple moving average of $0.92 and a 200 day simple moving average of $1.12. Nektar Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.93.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NKTR shares. Piper Sandler started coverage on Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a research note on Monday, January 13th. Finally, B. Riley started coverage on Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 target price on the stock. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Institutional Investors Weigh In On Nektar Therapeutics

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Nektar Therapeutics by 30.4% during the third quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 22,285 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Nektar Therapeutics by 5.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 650,841 shares of the biopharmaceutical company’s stock valued at $846,000 after purchasing an additional 34,599 shares in the last quarter. Intech Investment Management LLC bought a new stake in Nektar Therapeutics in the third quarter valued at $41,000. Valence8 US LP bought a new stake in Nektar Therapeutics in the third quarter valued at $34,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Nektar Therapeutics in the third quarter valued at $86,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.